Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration
Christina A. von Roemeling1, Laura A. Marlow1, Derek C. Radisky1, Austin Rohl1, Hege E. Larsen1, Johnny Wei1, Heather Sasinowska3, Heng Zhu5, Richard Drake4, Maciek Sasinowski3, Han W. Tun2 and John A. Copland1
1 Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida
2 Division of Hematology & Oncology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida
3 Incogen, Inc., Jacksonville, Florida
4 MUSC Proteomics Center, Jacksonville, Florida
5 Department of Pharmacology & Molecular Sciences, Johns Hopkins School of Medicine, Jacksonville, Florida
John A. Copland, email:
Keywords: Renal cell carcinoma, gene array, metastasis, therapeutic targets
Received: April 23, 2014 Accepted: June 11, 2014 Published: June 12, 2014
Currently there is a lack of targeted therapies that lead to long-term attenuation or regression of disease in patients with advanced clear cell renal cell carcinoma (ccRCC). Our group has implemented a high-throughput genetic analysis coupled with a high-throughput proliferative screen in order to investigate the genetic contributions of a large cohort of overexpressed genes at the functional level in an effort to better understand factors involved in tumor initiation and progression.
Patient gene array analysis identified transcripts that are consistently elevated in patient ccRCC as compared to matched normal renal tissues. This was followed by a high-throughput lentivirus screen, independently targeting 195 overexpressed transcripts identified in the gene array in four ccRCC cell lines. This revealed 31 ‘hits’ that contribute to ccRCC cell proliferation.
Many of the hits identified are not only presented in the context of ccRCC for the first time, but several have not been previously linked to cancer. We further characterize the function of a group of hits in tumor cell invasion. Taken together these findings reveal pathways that may be critical in ccRCC tumorigenicity, and identifies novel candidate factors that could serve as targets for therapeutic intervention or diagnostic/prognostic biomarkers for patients with advanced ccRCC.
Christina A. von Roemeling
Laura A. Marlow
Derek C. Radisky
Hege E. Larsen
Han W. Tun
John A. Copland
Primary Contact _
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
Copyright @ 2008-2014 Impact Journals, LLC. All rights reserved.